Autopsy report · NCT00780676

Personalized Treatment Selection for Metastatic Breast Cancer

“Closed early for futility.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 4 years 11 months before it stopped.
• 97 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Dasatinib; AZD6244

Participants

97

Sites

1

Countries

United States

Trials that died the same way

• Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
  “closed due to futility” (74% match in meaning)
• Pemetrexed Plus Gemcitabine in Renal Cell Cancer
  “Closed early for poor accrual.” (71% match in meaning)
• Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
  “Closed early due to low accrual.” (70% match in meaning)
• Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning
  “Closed early due to slow accrual.” (70% match in meaning)
• Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL
  “Closed early due to poor accrual.” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.